# CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

> **NCT06783309** · PHASE1,PHASE2 · RECRUITING · sponsor: **COUR Pharmaceutical Development Company, Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus
- T1D
- T1DM
- T1DM - Type 1 Diabetes Mellitus
- Type 1 Diabetes in Adolescence
- Type 1 Diabetes in Children
- Type 1 Diabetes (Juvenile Onset)
- Type 1 Diabetes
- Type 1 Diabetes Patients
- Type 1 Diabetes Mellitis

## Interventions

- **DRUG:** CNP-103
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06783309
- **Lead sponsor:** COUR Pharmaceutical Development Company, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783309, "CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06783309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*